Smart Insulin Pens Are Associated With Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis
figureposted on 2020-12-10, 11:03 authored by Johan Jendle, Åsa Ericsson, Jens Gundgaard, Jonas B. Møller, William J. Valentine, Barnaby Hunt
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.